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 Stabilizing atherosclerotic lesions and preventing plaque ruptures can be seen 
as the holy grail in vascular medicine. In this issue of Molecular Therapy, Jin et al 
suggest local delivery of a microRNA-21 (miR-21) mimic as a potential therapeutic 
strategy to reduce plaque vulnerability. Interestingly, inhibition of this microRNA has 
also been proposed as a therapeutic approach for in-stent restenosis, where the 
application of anti-miR-21 oligonucleotides on stents improved vessel patency1. 
 
Atherosclerosis is a chronic inflammatory disease resulting from the build-up 
of lipid deposits in the innermost layer of an artery. Apart from lipids, atherosclerotic 
plaques comprise mainly smooth muscle cells, macrophages, calcium and fibrous 
connective tissue.  Upon rupture or erosion of vulnerable atherosclerotic plaques, 
platelet aggregation results in thrombus formation that can occlude the vessel lumen. 
Stents are metallic scaffolds placed into the occluded segment of a diseased artery 
to hold it open. Current drug-eluting stents (DES) are designed to inhibit vascular 
smooth muscle cell (SMC) proliferation to reduce neo-intima formation within the 
stent lumen. Whilst greatly enhancing stent patency in coronary arteries, these anti-
proliferative agents also inhibit the proliferation of endothelial cells, thus delaying re-
endothelialization and arterial healing. After DES implantation, dual antiplatelet 
therapy is therefore required to prevent the inherent risk of thrombosis and stent 
occlusion. Alternatives to current DES that would inhibit SMC proliferation without 
delaying re-endothelialization should result in less thrombogenicity.  
 
In the vasculature, miR-21 has previously been implicated as a determinant of 
SMC proliferation2–5. For example, pharmacological and genetic miR-21 inhibition 
markedly decreased neo-intima formation in vein grafts4,5 and balloon-injured carotid 
arteries2. These findings led to the exploration of local therapeutic strategies by 
coating stents with miR-21 inhibitors. When deployed in denuded arteries in rats, this 
approach prevented SMC-mediated in-stent restenosis without delaying re-
endothelialization1. 
 
Conversely, SMC proliferation can also be beneficial in stabilizing the vessel 
wall and atherosclerotic plaques. For example, the proliferative effects of miR-21 
mimics in SMCs reduced the expansion of abdominal aortic aneurysms6. The results 
presented by Jin et al in this issue of the journal propose the use of miR-21 mimics 
to enhance plaque stability. Unstable human plaques and atherosclerotic lesions in 
apolipoprotein E (apoE) deficient mice (Apoe-/-) exhibit lower miR-21 levels. Based 
on in situ hybridization and immunohistochemistry, this expression pattern was 
ascribed to SMCs. The authors further show that plaques in Apoe/miR-21 double 
deficient mice (Apoe-/-miR21-/-) were more prone to rupture. Additionally, the 
unstable plaques were shown to harbor lower levels of the RE1-silencing 
transcription factor (REST). REST has been identified as a regulator of miR-21 whilst 
also being a direct target of miR-21. Subsequent in vitro analysis of SMCs revealed 
an anti-proliferative effect of REST, confirming the proliferative role of miR-21. 
Finally, local delivery of miR-21 mimics to carotid plaques using ultrasound-targeted 
microbubble destruction enhanced plaque stability. These findings suggest that by 
increasing SMC proliferation, miR-21 mimics could stabilize the SMC-rich fibrous cap 
that shields the lipid-filled core of atherosclerotic plaques. 
 
As is the case for most miRNAs, miR-21 is ubiquitously expressed7. It is 
particularly abundant in circulating hematopoietic cells, where it appears to act as an 
‘emergency brake’ on inflammation. In macrophages, miR-21 directly targets the pro-
inflammatory programmed cell death protein 4 (PDCD4), thereby increasing the 
secretion of anti-inflammatory interleukin-10 (IL-10)8. MiR-21 also directly targets 
phosphatase and tensin homolog (PTEN), steering macrophages towards a 
reparative phenotype that promotes resolution of inflammation and tissue recovery9. 
Thus, miR-21 may also modulate tissue inflammation, in part through monocyte 
differentiation toward an anti-inflammatory macrophage phenotype. 
 
A recent study by Canfrán-Duque et al also focused on miR-21 in the context 
of atherosclerosis10. MiR-21 accumulated in murine atherosclerotic plaques along 
with CD68, a macrophage marker. Deficiency of miR-21 in bone marrow cells 
promoted vascular inflammation and plaque necrosis in low-density lipoprotein 
receptor (LDLr) null mice. Compared to wild-type bone marrow, transplantation of 
miR-21-/- bone marrow into LDLr-/- mice resulted in larger and less stable 
atherosclerotic plaques due to increased inflammatory cell infiltration. Thus, miR-21 
expression in murine hematopoietic cells attenuates vascular inflammation. The 
findings of Jin et al also highlight the impact of miR-21 on the influx of macrophages. 
Apoe-/-miR21-/- mice displayed more advanced plaque formation at an early age, with 
a concomitant increase of macrophage infiltration and foam cell formation. In line 
with the recent findings of Canfrán-Duque et al, miR-21 null peritoneal macrophages 
displayed an increase in oxidized LDL uptake and foam cell formation through 
enhanced NF-kB signaling. Notably, secreted factors from Apoe-/-miR21-/- 
macrophages could suppress SMC proliferation in vitro. 
 A common challenge in miRNA research is to identify the cell types that are 
responsible for the observed therapeutic benefits. Although the present study 
confirms a mechanistic link between miR-21 and SMC proliferation, it remains 
unclear whether the beneficial effect relies predominantly on SMCs, macrophages or 
other cell types. Using a multi-omics approach, we recently identified a protein 
signature of symptomatic atherosclerotic plaques that implied a shared involvement 
of immune cells and SMCs11. Also, the plasticity of SMCs is currently under debate, 
with lineage tracing experiments suggesting a potential SMC origin of macrophage-
like cell types12,13. Finally, apoE mediates the reverse cholesterol transport14 and 
atherosclerosis is known to differ between man and apoE null mice15. 
 
Despite these notes of caution, the study by Jin et al advances our insight into 
the role of miR-21 in vascular biology. This is a timely contribution as miRNA-based 
therapies progress to clinical application. Clinical trials are currently underway in 
patients with Alport Syndrome, where systemic miR-21 inhibition is evaluated for the 
treatment of renal fibrosis. A better understanding of the effects of miR-21 in the 
context of other diseases is therefore highly relevant. The findings of Jin et al 
implicate that local therapy with miR-21 may indeed achieve higher drug 
concentrations at the target site and could minimize the risk of systemic side effects 
from miRNA therapeutics. Nevertheless, even local therapy for ubiquitously 
expressed miRNAs could have potential systemic effects, for example by affecting 
circulating cells in the blood stream. 
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Figure legends 
 
Figure 1. MicroRNA-21-based therapy for plaque vulnerability and in-stent 
restenosis. Delivery of microRNA-21 (miR-21) mimic to atherosclerotic plaques by 
ultrasound-targeted microbubble destruction (UTMD) enhances smooth muscle cell 
proliferation, whilst also steering monocytes towards a reparative, anti-inflammatory 
phenotype. Conversely, stents coated with miR-21 inhibitor (anti-miR-21) prevent in-
stent restenosis through their anti-proliferative effect on smooth muscle cells. 
 
 
References 
1. Wang, D., Deuse, T., Stubbendorff, M., Chernogubova, E., Erben, RG., Eken, 
SM., Jin, H., Li, Y., Busch, A., Heeger, C-H., et al. (2015). Local microRNA 
modulation using a novel anti-miR-21-eluting stent effectively prevents 
experimental in-stent restenosis. Arterioscler. Thromb. Vasc. Biol. 35: 1945–
53. 
2. Ji, R., Cheng, Y., Yue, J., Yang, J., Liu, X., Chen, H., Dean, DB. and Zhang, C. 
(2007). MicroRNA expression signature and antisense-mediated depletion 
reveal an essential role of MicroRNA in vascular neointimal lesion formation. 
Circ. Res. 100: 1579–1588. 
3. Wang, M., Li, W., Chang, G-Q., Ye, C-S., Ou, J-S., Li, X-X., Liu, Y., Cheang, 
T-Y., Huang, X-L. and Wang, S-M. (2011). MicroRNA-21 regulates vascular 
smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis 
obliterans of lower extremities. Arterioscler. Thromb. Vasc. Biol. 31: 2044–
2053. 
4. McDonald, RA., Halliday, CA., Miller, AM., Diver, LA., Dakin, RS., 
Montgomery, J., McBride, MW., Kennedy, S., McClure, JD., Robertson, KE., et 
al. (2015). Reducing in-stent restenosis: Therapeutic manipulation of miRNA in 
vascular remodeling and inflammation. J. Am. Coll. Cardiol. 65: 2314–2327. 
5. McDonald, RA., White, KM., Wu, J., Cooley, BC., Robertson, KE., Halliday, 
CA., McClure, JD., Francis, S., Lu, R., Kennedy, S., et al. (2013). miRNA-21 is 
dysregulated in response to vein grafting in multiple models and genetic 
ablation in mice attenuates neointima formation. Eur. Heart J. 34: 1636–1643. 
6. Maegdefessel, L., Azuma, J., Toh, R., Deng, A., Merk, DR., Raiesdana, A., 
Leeper, NJ., Raaz, U., Schoelmerich, AM., McConnell, M V., et al. (2012). 
MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-
augmented expansion. Sci. Transl. Med. 4: 122ra22. 
7. Barwari, T., Joshi, A. and Mayr, M. (2016). MicroRNAs in cardiovascular 
disease. J. Am. Coll. Cardiol. 68: 2577–2584. 
8. Sheedy, FJ., Palsson-McDermott, E., Hennessy, EJ., Martin, C., O’Leary, JJ., 
Ruan, Q., Johnson, DS., Chen, Y. and O’Neill, L a J. (2010). Negative 
regulation of TLR4 via targeting of the proinflammatory tumor suppressor 
PDCD4 by the microRNA miR-21. Nat. Immunol. 11: 141–147. 
9. Das, A., Ganesh, K., Khanna, S., Sen, CK. and Roy, S. (2014). Engulfment of 
apoptotic cells by macrophages: a role of microRNA-21 in the resolution of 
wound inflammation. J. Immunol. 192: 1120–9. 
10. Canfrán-Duque, A., Rotllan, N., Zhang, X., Fernández-Fuertes, M., Ramírez-
Hidalgo, C., Araldi, E., Daimiel, L., Busto, R., Fernández-Hernando, C. and 
Suárez, Y. (2017). Macrophage deficiency of miR-21 promotes apoptosis, 
plaque necrosis, and vascular inflammation during atherogenesis. EMBO Mol. 
Med. 9: 1244–1262. 
11. Langley, SR., Willeit, K., Didangelos, A., Matic, LP., Skroblin, P., Barallobre-
Barreiro, J., Lengquist, M., Rungger, G., Kapustin, A., Kedenko, L., et al. 
(2017). Extracellular matrix proteomics identifies molecular signature of 
symptomatic carotid plaques. J. Clin. Invest. 127: 1546–1560. 
12. Shankman, LS., Gomez, D., Cherepanova, OA., Salmon, M., Alencar, GF., 
Haskins, RM., Swiatlowska, P., Newman, AAC., Greene, ES., Straub, AC., et 
al. (2015). KLF4-dependent phenotypic modulation of smooth muscle cells has 
a key role in atherosclerotic plaque pathogenesis. Nat. Med. 21: 628–37. 
13. Bennett, MR., Sinha, S. and Owens, GK. (2016). Vascular smooth muscle 
cells in atherosclerosis. Circ. Res. 118: 692–702. 
14. Zanotti, I., Pedrelli, M., Potì, F., Stomeo, G., Gomaraschi, M., Calabresi, L. and 
Bernini, F. (2011). Macrophage, but not systemic, apolipoprotein E is 
necessary for macrophage reverse cholesterol transport in vivo. Arterioscler. 
Thromb. Vasc. Biol. 31: 74–80. 
15. Allahverdian, S., Pannu, PS. and Francis, GA. (2012). Contribution of 
monocyte-derived macrophages and smooth muscle cells to arterial foam cell 
formation. Cardiovasc. Res. 95: 165–72. 
 
